https://doi.org/10.55788/77e1ee32
Physical activity has been associated with clinical benefits for patients with COPD, however, it is unclear which type of intervention results in the largest behavioural change [1]. The current randomised-controlled trial, presented by Prof. Andre Nyberg (University of Umeå, Sweden), included 146 patients with COPD to evaluate the effect of a web-based support tool on physical activity [2]. In the control arm, participants received usual care, a folder about physical activity in COPD, and a step counter. In the intervention arm, the participants received the options from the control arm plus access to the so-called COPD Web, including information on the benefits of physical activity, how to increase physical activity, exercises, and reminder messages.
After 3 months, the web-based intervention led to a clinically relevant improvement in physical activity compared with the control arm (mean change +1,227 steps/day; 95% CI 90–2,365). In addition, 50% versus 28% of the participants in the experimental arm and the control arm achieved a minimal clinically important difference of >600 steps per day.
“These preliminary results show that a web-based, self-management support tool may lead to an objective, clinically relevant improvement in physical activity in the short term compared with usual care,” concluded Prof. Nyberg. “Furthermore, interview-based information teaches us that patients in the intervention arm felt an increased sense of control to improve their physical activity level by being able to use the web-based tool we developed.”
- Burge AT, et al. Cochrane Database Syst Rev. 2020;4(4):CD012626.
- Stenlund T, et al. Clinically relevant effects on physical activity with web-based self-management support in people with COPD: a randomized controlled trial. ALERT 2, RCT2160, ERS International Congress 2022, Barcelona, Spain, 4–6 September.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Hyperpolarised gas MRI ready for clinical use Next Article
COPD medication not effective in symptomatic smokers with preserved spirometry »
« Hyperpolarised gas MRI ready for clinical use Next Article
COPD medication not effective in symptomatic smokers with preserved spirometry »
Table of Contents: ERS 2022
Featured articles
Letter from the Editor
COVID-19: What Is New?
Does vilobelimab reduce mortality in severe COVID-19?
Awake proning not positive in COVID-19
Favipiravir may help patients over 60 years with COVID-19 to recover
Inhaled agent under investigation for COVID-19
Accurate voice-based COVID-19 diagnostic test in development
Novel scoring tool for post-COVID syndrome aids clinicians and researchers
COPD: Therapies and Innovations
Icenticaftor achieves results on top of triple inhalation therapy in COPD
STARR2: A new approach for treating COPD exacerbations
COPD medication not effective in symptomatic smokers with preserved spirometry
Do digital tools improve physical activity in COPD?
Hyperpolarised gas MRI ready for clinical use
All About Asthma
Tezepelumab in asthma: mucus plugging down, lung function up
Digital asthma intervention improves health and reduces costs
Digitally enhanced therapy lowers treatment burden and costs in severe asthma
Mepolizumab beneficial for patients with severe eosinophilic asthma
Progress in Paediatrics
Antibiotics cause increased risk of wheezing in severe RSV bronchiolitis
Inhaled corticosteroids useful in preterms with decreased lung function
Fish oil or vitamin D during pregnancy can prevent croup
Encouraging results of nintedanib in children with fibrosing ILD
Focus on Interventional Pulmonology
Head-to-head: lung volume reduction surgery vs endobronchial valves
Durable effect of endobronchial valves in severe emphysema
Cone beam CT-guided ENB improves detection of pulmonary nodules
Confirmatory mediastinoscopy not needed in resectable NSCLC
Sleep and Breathing Disorders
In the spotlight: Cancer trends in obstructive sleep apnoea
Impact of CPAP on cardiac endpoints in OSA
Sustained hypoxaemia predicts unprovoked VTE in OSA
CPAP therapy in the prevention of cardiovascular risk in patients with OSA
Other Remarkable Research
Excellent results for high-flow nasal cannula oxygen therapy in acute respiratory failure
Antifibrotic therapy may slow down FVC decline in RAILD
Intravenous N-acetylcysteine performs well in hospitalised patients
Men and women respond differently to diesel exhaust
New trends in cystic lung diseases
Related Articles
October 30, 2022
Mepolizumab beneficial for patients with severe eosinophilic asthma
July 18, 2022
COVI-PRONE trial on its back
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com